<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Opicapone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Opicapone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Opicapone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="128063" href="/d/html/128063.html" rel="external">see "Opicapone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54809542"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ongentys</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54346822"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anti-Parkinson Agent, COMT Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F54444141"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="afdbcf58-54a4-4f1f-8310-d12811c549e2">Parkinson disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease: Oral:</b> 50 mg once daily at bedtime.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54444143"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution in severe impairment. Avoid use in patients with end-stage renal disease (CrCl &lt;15 mL/minute).</p></div>
<div class="block doha drugH1Div" id="F54444144"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate (Child-Pugh class B): 25 mg once daily at bedtime.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe (Child-Pugh class C): Avoid use (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F54444142"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F55592828"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Dyskinesia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">New-onset or exacerbation of preexisting <b>dyskinesia</b> was the most common adverse effect of opicapone, in combination with levodopa, as well as the most common adverse event leading to discontinuation in clinical trials; most of the dyskinesia events occurred in patients already experiencing dyskinesia at baseline during clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28027332','lexi-content-ref-31498127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28027332','lexi-content-ref-31498127'])">Ref</a></span>). During clinical trials, most of the gain of on-time with opicapone was <i>without</i> troublesome dyskinesia; in addition, there was no significant difference between placebo and opicapone with regards to the increase in on-time <i>with</i> troublesome dyskinesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30264443','lexi-content-ref-30681754','lexi-content-ref-28027332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30264443','lexi-content-ref-30681754','lexi-content-ref-28027332'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, potentiation of dopaminergic effects) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.2012'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; most dyskinetic events occurred within the first 4 weeks of treatment in clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31498127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31498127'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses of levodopa</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of other dopaminergic drugs</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting dyskinesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28027332','lexi-content-ref-31498127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28027332','lexi-content-ref-31498127'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Impulse control disorders</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Impulse control disorder</b> (ICD) and/or compulsive behaviors, which may manifest as pathological gambling, hypersexuality, intense urges to spend money uncontrollably, and other intense urges, have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26725544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26725544'])">Ref</a></span>). In some cases, the behavior will subside with a dose reduction or discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, potentiation of dopaminergic effects) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32354771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32354771'])">Ref</a></span>). The impact of the disease process and concurrent medications must be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31057473','lexi-content-ref-32354771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31057473','lexi-content-ref-32354771'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Variable; based on clinical experience, onset of dopaminergic adverse effects often occurs within the first several weeks following initiation of catechol-O-methyltransferase inhibitor therapy; onset may be dependent on the presence of patient risk factors and concomitant medications.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• In general, the following are potentially associated with Parkinson disease-impulse control behaviors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31057473','lexi-content-ref-32354771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31057473','lexi-content-ref-32354771'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">- Concomitant use of dopamine agonists</p>
<p style="text-indent:-2em;margin-left:8em;">- Concomitant use of levodopa use; <b>Note: </b>Some studies have failed to find an association or strong association with the use of levodopa and the risk of ICD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23283708','lexi-content-ref-29925549','lexi-content-ref-31167116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23283708','lexi-content-ref-29925549','lexi-content-ref-31167116'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Duration of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29925549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29925549'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Younger age</p>
<p style="text-indent:-2em;margin-left:8em;">- Male patients</p>
<p style="text-indent:-2em;margin-left:8em;">- Comorbid depression</p>
<p style="text-indent:-2em;margin-left:8em;">- Comorbid anxiety</p>
<p style="text-indent:-2em;margin-left:6em;">• Suspected or diagnosed dopamine dysregulation syndrome</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Opicapone, in combination with levodopa, may cause <b>orthostatic hypotension</b>; orthostatic hypotension has resulted in treatment discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28027332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28027332'])">Ref</a></span>). In addition, nonorthostatic <b>hypotension, presyncope</b>, and <b>syncope </b>have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, potentiation of dopaminergic effects) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.2012'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of other hypotensive agents</p>
<p style="text-indent:-2em;margin-left:6em;">• In general, the following risk factors may increase the likelihood of orthostatic hypotension in Parkinson disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22336566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22336566'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Age &gt;68 years</p>
<p style="text-indent:-2em;margin-left:8em;">- Polypharmacy (use of &gt;5 medications)</p>
<p style="text-indent:-2em;margin-left:8em;">- Concomitant use of amantadine or diuretics</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Concomitant use of entacapone, another catechol-O-methyltransferase inhibitor, appeared to reduce the risk of orthostatic hypotension in this study.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Psychiatric effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of opicapone, in combination with levodopa, may result in <b>hallucinations,</b> including <b>auditory hallucinations</b>, <b>visual hallucinations</b>, or mixed hallucinations; may also cause <b>aggressive behavior,</b>
<b>agitation,</b> or <b>delusions.</b> During one clinical trial, visual hallucinations resulted in treatment discontinuation in several patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31498127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31498127'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, potentiation of dopaminergic effects) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.2012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Variable; based on clinical experience, onset of dopaminergic adverse effects often occurs within the first several weeks following initiation of catechol-O-methyltransferase inhibitor therapy; onset may be dependent on the presence of patient risk factors and concomitant medications.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of a major psychotic disorder</p>
<p style="text-indent:-2em;margin-left:6em;">• Age ≥70 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30264443','lexi-content-ref-31498127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30264443','lexi-content-ref-31498127'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of other agents known to cause psychiatric effects (eg, dopaminergic agonists, anticholinergic agents)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sudden onset of sleep</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Opicapone, when added to levodopa, may result in a <b>sudden onset of sleep</b> while engaging in activities of daily living, including <b>sleep driving</b>; events have been reported to occur without significant warning signs and may result in accidents. Patients may report feeling alert immediately prior to events.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, potentiation of dopaminergic effects).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; based on clinical experience, onset may occur within the first several weeks of treatment with catechol-O-methyltransferase (COMT) inhibitors but may also develop years later in some patients. One case report described onset of irresistible sleep episodes 3 days following initiation of entacapone, another COMT inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12588639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12588639'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting sleep disorder</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of other sedating agents</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54357223"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Neuromuscular &amp; skeletal: Dyskinesia (20%; severe dyskinesia: 1% [Lees 2019])<span class="lexi-table-link-container"> (<a aria-label="Opicapone: Adverse Reaction: Dyskinesia table link" class="lexi-table-link" data-table-id="lexi-content-opicapone-adverse-reaction-dyskinesia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-opicapone-adverse-reaction-dyskinesia')">table 1</a>)</span><span class="table-link" style="display:none;">Opicapone: Adverse Reaction: Dyskinesia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Opicapone: Adverse Reaction: Dyskinesia" frame="border" id="lexi-content-opicapone-adverse-reaction-dyskinesia" rules="all">
<caption style="text-align:center;">
<b>Opicapone: Adverse Reaction: Dyskinesia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Opicapone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Opicapone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Source</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">265</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">257</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ongentys PI 2020.04</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">322</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">147</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Lees 2019</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (3%), hypotension (including orthostatic hypotension, presyncope, syncope: 5%)<span class="lexi-table-link-container"> (<a aria-label="Opicapone: Adverse Reaction: Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-opicapone-adverse-reaction-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-opicapone-adverse-reaction-hypotension')">table 2</a>)</span><span class="table-link" style="display:none;">Opicapone: Adverse Reaction: Hypotension</span>, increased serum creatine kinase (5%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Opicapone: Adverse Reaction: Hypotension" frame="border" id="lexi-content-opicapone-adverse-reaction-hypotension" rules="all">
<caption style="text-align:center;">
<b>Opicapone: Adverse Reaction: Hypotension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Opicapone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Opicapone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">265</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">257</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Including orthostatic hypotension, presyncope, syncope</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (6%), xerostomia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (3%), hallucination (including auditory hallucinations, visual hallucinations: 3%<span class="lexi-table-link-container"> (<a aria-label="Opicapone: Adverse Reaction: Hallucination table link" class="lexi-table-link" data-table-id="lexi-content-opicapone-adverse-reaction-hallucination" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-opicapone-adverse-reaction-hallucination')">table 3</a>)</span><span class="table-link" style="display:none;">Opicapone: Adverse Reaction: Hallucination</span>), impulse control disorder (1%)<span class="lexi-table-link-container"> (<a aria-label="Opicapone: Adverse Reaction: Impulse Control Disorder table link" class="lexi-table-link" data-table-id="lexi-content-opicapone-adverse-reaction-impulse-control-disorder" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-opicapone-adverse-reaction-impulse-control-disorder')">table 4</a>)</span><span class="table-link" style="display:none;">Opicapone: Adverse Reaction: Impulse Control Disorder</span>, insomnia (3%), psychosis (including aggressive behavior, agitation, delusion: 1%)<span class="lexi-table-link-container"> (<a aria-label="Opicapone: Adverse Reaction: Psychosis table link" class="lexi-table-link" data-table-id="lexi-content-opicapone-adverse-reaction-psychosis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-opicapone-adverse-reaction-psychosis')">table 5</a>)</span><span class="table-link" style="display:none;">Opicapone: Adverse Reaction: Psychosis</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Opicapone: Adverse Reaction: Hallucination" frame="border" id="lexi-content-opicapone-adverse-reaction-hallucination" rules="all">
<caption style="text-align:center;">
<b>Opicapone: Adverse Reaction: Hallucination</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Opicapone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Opicapone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">265</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">257</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Including auditory hallucination, visual hallucination, mixed hallucination</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Opicapone: Adverse Reaction: Impulse Control Disorder" frame="border" id="lexi-content-opicapone-adverse-reaction-impulse-control-disorder" rules="all">
<caption style="text-align:center;">
<b>Opicapone: Adverse Reaction: Impulse Control Disorder</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Opicapone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Opicapone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">265</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">257</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Opicapone: Adverse Reaction: Psychosis" frame="border" id="lexi-content-opicapone-adverse-reaction-psychosis" rules="all">
<caption style="text-align:center;">
<b>Opicapone: Adverse Reaction: Psychosis</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Opicapone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Opicapone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">265</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">257</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Including aggressive behavior, agitation, delusion</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Nervous system: Sleep driving, sudden onset of sleep</p></div>
<div class="block coi drugH1Div" id="F54346825"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concomitant use of nonselective monoamine oxidase inhibitors; pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F54444122"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment; avoid use in severe impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution in patients with severe renal impairment; discontinue opicapone if tolerability issues arise. Avoid use in patients with end-stage renal disease (CrCl &lt;15 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome upon withdrawal or abrupt dosage reduction; patients should be monitored closely if therapy is discontinued.</p></div>
<div class="block foc drugH1Div" id="F54809543"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ongentys: 25 mg, 50 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p></div>
<div class="block geq drugH1Div" id="F54809541"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54868175"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Ongentys Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $26.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $26.81</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F54444145"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer at bedtime; do not eat for 1 hour before and at least 1 hour after dose.</p></div>
<div class="block use drugH1Div" id="F54346824"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Parkinson disease:</b> Adjunctive treatment to levodopa/carbidopa in patients with Parkinson disease experiencing “off” episodes.</p></div>
<div class="block mst drugH1Div" id="F54444118"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Opicapone may be confused with entacapone or tolcapone.</p>
<p style="text-indent:0em;margin-left:2em;">Ongentys (brand name for opicapone) may be confused with Onglyza (brand name for saxagliptin).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54367787"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, MRP2, OATP1B1/1B3 (SLCO1B1/1B3), OATP2B1/SLCO2B1, P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> COMT</p></div>
<div class="block dri drugH1Div" id="F54367784"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COMT Substrates: COMT Inhibitors may increase the serum concentration of COMT Substrates. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: Opicapone may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: COMT Inhibitors may diminish the therapeutic effect of Pipamperone [INT]. Pipamperone [INT] may diminish the therapeutic effect of COMT Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F54444129"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food decreases the rate and extent of absorption of opicapone. Management: Do not eat for 1 hour before and at least 1 hour after opicapone.</p></div>
<div class="block pri drugH1Div" id="F54444120"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to opicapone may cause fetal harm. Opicapone is used in combination with levodopa/carbidopa. Also refer to the Levodopa/Carbidopa monographs for additional information.</p></div>
<div class="block brc drugH1Div" id="F54444121"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if opicapone is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Opicapone is used in combination with levodopa/carbidopa. Also refer to the Levodopa/Carbidopa monographs for additional information.</p></div>
<div class="block mop drugH1Div" id="F54444147"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Liver and renal function tests (baseline and as clinically indicated); BP (baseline and as clinically indicated); mental alertness, daytime somnolence, preexisting sleep disorder.</p></div>
<div class="block pha drugH1Div" id="F54444131"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Opicapone is a reversible and selective inhibitor of catechol-O-methyltransferase (COMT); COMT is the major degradation pathway for levodopa. When opicapone is taken with levodopa, the pharmacokinetics are altered, resulting in more sustained levodopa serum levels compared to levodopa taken alone. The resulting levels of levodopa provide for increased concentrations available for absorption across the blood-brain barrier, thereby providing for increased CNS levels of dopamine, the active metabolite of levodopa.</p></div>
<div class="block phk drugH1Div" id="F54444132"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: With a moderate-fat/moderate-calorie meal, the mean C<sub>max</sub> decreased 62%, AUC decreased 31%, and the T<sub>max</sub> was delayed by 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Via sulphation (primarily), glucuronidation, methylation, reduction, and glutathione concentration.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 hours (range: 1 to 4 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: ~70% (22% as unchanged drug); expired air: 20%; urine: 5% (&lt;1% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F54444139"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function impairment: AUC increased by 35% in mild impairment (Child-Pugh class A) and 84% in moderate impairment (Child-Pugh class B).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F54383620"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ongentys | Ontilyv</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ongentys</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-23283708">
<a name="23283708"></a>Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson's disease. <i>Mov Disord</i>. 2013;28(3):327-333. doi:10.1002/mds.25291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/opicapone-drug-information/abstract-text/23283708/pubmed" id="23283708" target="_blank">23283708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29925549">
<a name="29925549"></a>Corvol JC, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. <i>Neurology</i>. 2018;91(3):e189-e201. doi:10.1212/WNL.0000000000005816<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/opicapone-drug-information/abstract-text/29925549/pubmed" id="29925549" target="_blank">29925549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EMA.2012">
<a name="EMA.2012"></a>European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease. Updated June 21, 2012. Accessed March 11, 2021. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-parkinsons-disease_en-0.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30264443">
<a name="30264443"></a>Fabbri M, Ferreira JJ, Lees A, et al. Opicapone for the treatment of Parkinson's disease: a review of a new licensed medicine. <i>Mov Disord</i>. 2018;33(10):1528-1539. doi:10.1002/mds.27475<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/opicapone-drug-information/abstract-text/30264443/pubmed" id="30264443" target="_blank">30264443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26725544">
<a name="26725544"></a>Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. <i>Lancet Neurol</i>. 2016;15(2):154-165. doi:10.1016/S1474-4422(15)00336-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/opicapone-drug-information/abstract-text/26725544/pubmed" id="26725544" target="_blank">26725544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30681754">
<a name="30681754"></a>Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. <i>Eur J Neurol</i>. 2019;26(7):953-960. doi:10.1111/ene.13914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/opicapone-drug-information/abstract-text/30681754/pubmed" id="30681754" target="_blank">30681754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31057473">
<a name="31057473"></a>Gatto EM, Aldinio V. Impulse control disorders in Parkinson's disease. a brief and comprehensive review. <i>Front Neurol</i>. 2019;10:351. doi:10.3389/fneur.2019.00351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/opicapone-drug-information/abstract-text/31057473/pubmed" id="31057473" target="_blank">31057473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32354771">
<a name="32354771"></a>Kelly MJ, Baig F, Hu MT, Okai D. Spectrum of impulse control behaviours in Parkinson's disease: pathophysiology and management. <i>J Neurol Neurosurg Psychiatry</i>. 2020;91(7):703-711. doi:10.1136/jnnp-2019-322453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/opicapone-drug-information/abstract-text/32354771/pubmed" id="32354771" target="_blank">32354771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31498127">
<a name="31498127"></a>Lees A, Ferreira JJ, Rocha JF, et al. Safety profile of opicapone in the management of Parkinson's disease. <i>J Parkinsons Dis</i>. 2019;9(4):733-740. doi:10.3233/JPD-191593<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/opicapone-drug-information/abstract-text/31498127/pubmed" id="31498127" target="_blank">31498127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28027332">
<a name="28027332"></a>Lees AJ, Ferreira J, Rascol O, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. <i>JAMA Neurol</i>. 2017;74(2):197-206. doi:10.1001/jamaneurol.2016.4703<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/opicapone-drug-information/abstract-text/28027332/pubmed" id="28027332" target="_blank">28027332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31167116">
<a name="31167116"></a>Liu B, Luo W, Mo Y, Wei C, Tao R, Han M. Meta-analysis of related factors of impulse control disorders in patients with Parkinson's disease. <i>Neurosci Lett</i>. 2019;707:134313. doi:10.1016/j.neulet.2019.134313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/opicapone-drug-information/abstract-text/31167116/pubmed" id="31167116" target="_blank">31167116</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ongentys (opicapone) [prescribing information]. San Diego, CA: Neurocrine Biosciences Inc; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22336566">
<a name="22336566"></a>Perez-Lloret S, Rey MV, Fabre N, et al. Factors related to orthostatic hypotension in Parkinson's disease. <i>Parkinsonism Relat Disord</i>. 2012;18(5):501-505. doi:10.1016/j.parkreldis.2012.01.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/opicapone-drug-information/abstract-text/22336566/pubmed" id="22336566" target="_blank">22336566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12588639">
<a name="12588639"></a>Santens P. Sleep attacks in Parkinson's disease induced by Entacapone, a COMT-inhibitor. <i>Fundam Clin Pharmacol</i>. 2003;17(1):121-123. doi:10.1046/j.1472-8206.2003.00121.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/opicapone-drug-information/abstract-text/12588639/pubmed" id="12588639" target="_blank">12588639</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 128042 Version 99.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
